Startseite › Brustkrebs › Wisconsin › Madison
Klinische Studien zu Brustkrebs in Madison, WI
22 Studien zu Brustkrebs suchen Teilnehmer an Standorten in und um Madison (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Teilnehmer gesuchtPhase 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Teilnehmer gesuchtPhase 1/2
- University of Wisconsin Carbone Cancer Center, Madison
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Teilnehmer gesuchtPhase 2
- UW Health Carbone Cancer Center, Madison
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Teilnehmer gesuchtPhase 2
- University of Wisconsin, Madison
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- Wisconsin Institute for Medical Research, Madison
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Teilnehmer gesuchtPhase 3
- Circuit Clinical/SSM Health Dean Medical Group ( Site 0039), Madison
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Teilnehmer gesuchtPhase 3
- University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0040), Madison
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Teilnehmer gesuchtPhase 3
- University of Wisconsin-Madison ( Site 0024), Madison
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Teilnehmer gesucht
- University of Wisconsin, Madison
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Teilnehmer gesuchtPhase 1
- University of Wisconsin - Carbone Cancer Center, Madison
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Teilnehmer gesuchtPhase 3
- University of Wisconsin Carbone Cancer Center- University Hospital, Madison
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- University of Wisconsin-Madison Carbone Cancer Center, Madison
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Teilnehmer gesuchtPhase 2
- University of Wisconsin, Madison
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Teilnehmer gesuchtPhase 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of 18F-FFNP Breast PET/MRI
Teilnehmer gesuchtPhase 2
- UW Carbone Cancer Center, Madison
Biomarkers to Detect Endocrine Therapy Resistance
Teilnehmer gesuchtPhase 2
- UW Carbone Cancer Center, Madison
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
Teilnehmer gesuchtPhase 2
- University of Wisconsin Carbone Cancer Center, Madison
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Teilnehmer gesuchtPhase 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Teilnehmer gesuchtBeobachtungsstudie
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Teilnehmer gesuchtPhase 4
- University of Wisconsin, Madison
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Teilnehmer gesuchtPhase 1
- UW Carbone Cancer Center, Madison
Brustkrebs-Studien in anderen Städten
- New York City, NY136 Studien
- Houston, TX126 Studien
- Boston, MA112 Studien
- Nashville, TN81 Studien
- Los Angeles, CA73 Studien
- Edison, NJ68 Studien
- St. Louis, MO64 Studien
- Queens, NY64 Studien
- Durham, NC64 Studien
- Chicago, IL59 Studien
- Philadelphia, PA56 Studien
- Dallas, TX55 Studien
Weitere Studien in Madison
- Prostatakrebs29 Studien
- Kolorektales Karzinom23 Studien
- Metastasierender Krebs21 Studien
- Akute myeloische Leukämie16 Studien
- Nichtkleinzelliges Lungenkarzinom16 Studien
- Melanom15 Studien
- Krebs (alle Arten)14 Studien
- Eierstockkrebs13 Studien
- Magenkrebs11 Studien
- Bauchspeicheldrüsenkrebs10 Studien
- Lungenkrebs10 Studien
- Multiples Myelom9 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.